Revised precautions issued by Japan's PMDA

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2016年 / 1620卷 / 1期

关键词：

D O I：

10.1007/s40278-016-21371-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：5 / 5

相关论文

共 50 条

[31] Japan's PMDA investigation results: June 2018
Reactions Weekly, 2018, 1706 (1) : 4 - 4
[32] RAS inhibitors: additional precautions for use in women of child-bearing potential issued in Japan
Reactions Weekly, 2023, 1961 (1) : 6 - 6
[33] The PMDA's view on the limited pipeline of nephrology drugs in Japan
Tanaka, Mototsugu
Ikuma, Mutsuhiro
KIDNEY INTERNATIONAL, 2021, 100 (01) : 241 - 242
[34] Japan's PMDA releases updated risk report for telaprevir
Reactions Weekly, 2012, 1408 (1) : 2 - 2
[35] Japan's PMDA releases investigation results for 4 products
Reactions Weekly, 2015, 1541 (1) : 5 - 5
[36] Japan's PMDA releases investigation results for 4 products
Reactions Weekly, 2016, 1590 (1) : 3 - 3
[37] Package insert revisions required: Japan's PMDA findings
Reactions Weekly, 2016, 1615 (1) : 4 - 4
[38] Japan's PMDA revises package inserts for memantine, bevacizumab
Reactions Weekly, 2020, 1810 (1) : 2 - 2
[39] Japan's PMDA releases investigation results for 8 products
Reactions Weekly, 2016, 1595 (1) : 5 - 5
[40] Japan's MHLW/PMDA recommends package insert revisions
Reactions Weekly, 2018, 1732 (1) : 1 - 1

← 1 2 3 4 5 →